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Estimating the scale of chronic hepatitis C
virus infection in the EU/EEA: a focus on
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Abstract
Background: Increasing the proportion diagnosed with and on treatment for chronic hepatitis C (CHC) is key to
the elimination of hepatitis C in Europe. This study contributes to secondary prevention planning in the European Union/
European Economic Area (EU/EEA) by estimating the number of CHC (anti-HCV positive and viraemic) cases among
migrants living in the EU/EEA and born in endemic countries, defining the most affected migrant populations, and
assessing whether country of birth prevalence is a reliable proxy for migrant prevalence.
Methods: Migrant country of birth and population size extracted from statistical databases and anti-HCV prevalence in
countries of birth and in EU/EEA countries derived from a systematic literature search were used to estimate caseload
among and most affected migrants. Reliability of country of birth prevalence as a proxy for migrant prevalence was
assessed via a systematic literature search.
Results: Approximately 11% of the EU/EEA adult population is foreign-born, 79% of whom were born in endemic (anti-
HCV prevalence ≥1%) countries. Anti-HCV/CHC prevalence in migrants from endemic countries residing in the EU/EEA is
estimated at 2.3%/1.6%, corresponding to ~580,000 CHC infections or 14% of the CHC disease burden in the EU/EEA.
The highest number of cases is found among migrants from Romania and Russia (50–60,000 cases each) and migrants
from Italy, Morocco, Pakistan, Poland and Ukraine (25–35,000 cases each). Ten studies reporting prevalence in migrants in
Europe were identified; in seven of these estimates, prevalence was comparable with the country of birth prevalence and
in three estimates it was lower.
Discussion: Migrants are disproportionately affected by CHC, account for a considerable number of CHC infections in
EU/EEA countries, and are an important population for targeted case finding and treatment. Limited data suggest that
country of birth prevalence can be used as a proxy for the prevalence in migrants.
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Background
Chronic infection with the hepatitis C virus (HCV) is a
global public health challenge and a leading cause of
liver disease-related morbidity and mortality. The
epidemiology remains poorly understood, however, and
global, national and risk group-specific anti-HCV and
viraemic prevalence estimates vary considerably. Recent
studies suggest that between 105 million and 185 million
people are anti-HCV positive worldwide and that global
anti-HCV prevalence in adults could be as high as 2%
[1, 2]. The Global Burden of Disease study estimated
that chronic HCV (CHC) infection causes almost half a
million deaths annually and is the 25th leading cause of
death worldwide [3].
Chronic HCV infection affects the liver and has a
mostly asymptomatic onset, but can lead to cirrhosis
and hepatocellular carcinoma (HCC) decades later [4].
The asymptomatic nature of infection and the lack of
adequate screening programmes means that the majority
of people infected with CHC are unaware of their
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infection and only around one third of all estimated
CHC infections in Europe have been diagnosed [5–7].
Effective antiviral treatment can prevent the develop-
ment of cirrhosis and HCC and, with newer direct acting
antivirals (DAAs) reporting cure rates in more than 90%
of cases, [8] the elimination of HCV infection is now
possible in Europe [9]. This will require continued
primary prevention of new infections in parallel with
expansion of secondary prevention through effective
screening, linkage to care and treatment.
Primary prevention measures in Europe, including a
safe blood supply, improved infection control practices
and harm reduction programmes, have led to a signifi-
cant reduction of HCV transmission in many countries
and a mathematical modelling study shows incident
cases are declining [10]. Incident data is not systematic-
ally collected and reported in most EU/EEEA countries
hampering a good understanding of time trends
although iatrogenic and nosocomial transmission is
reported to be rare in most EU/EEA countries [11].
However, models predict that the peak in the mortality
is yet to be reached [9, 10, 12]. An estimated 7.4 million
people are anti-HCV positive in the European Union/
European Economic area (EU/EEA), although prevalence
varies from 0.9% in Western Europe to 3.3% in Eastern
Europe [1, 13]. Deaths from viral hepatitis now exceed
those from HIV and tuberculosis combined and latest
published estimates show that 96,000 people die each
year in EU/EEA countries from HBV and HCV-related
liver disease [3]. Some populations are disproportion-
ately affected and have a high prevalence of chronic in-
fection. One such population is migrants born in high
anti-HCV prevalence countries [10, 14–16], although es-
timates of the number of cases and the most affected
migrant populations in Europe are lacking.
This epidemiological study seeks to inform targeted
screening, linkage to care and treatment in the EU/EEA
by: providing estimates, across and within all 31 EU/
EEA countries, of the number of CHC cases among mi-
grants from countries where anti-HCV prevalence is
≥1%; providing an estimate of the relative contribution
of migrants to the overall burden of disease; and com-
paring the reported in-country of birth prevalence with
that found among migrants living in European countries.
In a sister paper to this, we conduct a similar analysis
for chronic hepatitis B among migrants from endemic
countries.
Methods
The data retrieval and analysis process are described in
detail below and in a schematic representation (Fig. 1).
Demographic data on the size of and countries of birth
of migrant populations were extracted from statistical
databases. Country of birth-specific and EU/EEA
country general population anti-HCV prevalence esti-
mates were derived from a systematic literature search.
To assess the reliability of using country of birth-derived
prevalence as a proxy for the prevalence among mi-
grants, a systematic literature search was conducted to
identify prevalence estimates among migrants in Europe
to compare with country of birth-derived prevalence.
Definitions
Migrant
An adult 15 years old or above, born in a country other
than the current country of residence. Children are ex-
cluded due to the dominance of older age populations in
sero-prevalence studies and the higher prevalence re-
ported among adults than among children [1]. The use
of the term ‘migrant’ in this study therefore refers to
adult (foreign-born) migrants only. The study accounts
for and includes migration from outside the EU/EEA
and migration within the EU/EEA, but excludes undocu-
mented migrants.
Anti-HCV prevalence
The common measure of exposure to HCV/endemicity
used in sero-prevalence studies. Anti-HCV prevalence can
include exposed individuals with a resolved infection.
Chronic hepatitis C (CHC)
Refers to viraemic infection, i.e. anti-HCV and HCV-
RNA positivity. Endemic country: the anti-HCV preva-
lence in the general adult population is ≥1%. This
relatively low threshold was chosen to take into account
migrants from countries where prevalence is higher than
that of the EU/EEA as a whole.
Part 1: The contribution of migrants from endemic
countries to the burden of CHC in the EU/EEA
Demographic data (Step 1)
The size and country of birth of the migrant population
was obtained for all 31 EU/EEA countries from Eurostat
for 2013, if available [17]. Where data were unavailable,
either the ‘EU 2011 – Housing and Population Census’,
the most recent demographic data from the Organisa-
tion for Economic Co-operation and Development
(OECD) Stats website or national statistics were used, in
that order [18–20]. The data source is indicated in foot-
notes in Table 1. For each EU/EEA country, the coun-
tries of birth of migrants were sorted into descending
order of magnitude of the number of migrants, and the
top 50 countries of birth by migrant population size
were then selected for estimating the CHC burden.
Country-specific anti-HCV prevalence (Step 2)
The online databases Medline, Embase, the Cochrane li-
brary, Web of Science, Scopus, PubMed publisher and
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Fig. 1 Schematic methodological representation to estimating the burden of CHC among migrants in the EU/EEA
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Google Scholar were searched in January 2015 for
reviews, systematic reviews and meta-analyses in English
about the prevalence of hepatitis C in the general popu-
lation at country level. The search (described in full in
Annex 1 of the Additional file 1) used a combination of
disease-related (hepatitis C), outcome-related (preva-
lence), population-related (general population, world-
wide) and study design-related (reviews) terms. Note
that the search also included terms related to hepatitis B
since we conducted a similar analysis for chronic hepa-
titis B among migrants from endemic countries (to be
published in this journal). Since the aim was to identify
recent reviews, the search was restricted to papers pub-
lished after 2009 to the date of the search. The titles and
abstracts, then the full text, of retrieved citations were
assessed for relevancy by one reviewer (AF). Key exclu-
sion criteria included studies focused on: hepatitis other
than type C; natural history, clinical features or compli-
cations of hepatitis; medical treatment; other high risk
groups e.g. people who inject drugs (PWID); and single
case studies and cost effectiveness analyses. High quality
systematic reviews/meta-analyses were selected given the
recent publication of robust systematic reviews/meta-
analyses of national level prevalence estimates globally.
Country-level anti-HCV prevalence estimates and
uncertainty ranges/confidence intervals (CIs) were ex-
tracted from the included reviews and entered into a
Microsoft Excel database of all countries. Where a
country-specific estimate was unavailable, the relevant
Global Burden of Disease region estimate was used. If a
meta-analysis reported a statistically significant time
trend, the estimate from the most recent period was se-
lected. Where multiple estimates for a country were
available from different reviews, the most robust was
selected based on the assessed risk of selection bias. Risk
of selection bias was assessed based on: sampling
method (random favoured over convenience); sampling
population (the general population was favoured over
more specifically defined (risk) groups); geographical
coverage (national favoured over regional; regional
favoured over local); sample size (larger studies preferred
over smaller one); and data collection timeframe (favour-
ing recency). Decisions were made jointly by two
reviewers (AF and IV) based on these criteria (rather
than a pre-defined algorithm) with a detailed rationale
recorded for each selected estimate. This rationale,
together with search strategy, the inclusion/exclusion
criteria and a PRISMA flowchart are available in the
online supplement.
Estimating the CHC burden among migrants from endemic
countries
Anti-HCV prevalence was multiplied by the number of
migrants from the top 50 countries of birth of migrants
in each EU/EEA country. The countries of birth were
then sorted in descending order of magnitude by anti-
HCV prevalence to identify all endemic (≥1% anti-HCV
prevalence) countries. The total number of migrants
born in anti-HCV endemic countries was used to deter-
mine both the total and proportional contribution of
migrants from these countries to the overall number of
migrants residing in each of the 31 EU/EEA countries.
To estimate the proportion of CHC (viraemic) cases
among the anti-HCV positive migrant population, the
worldwide average viraemic proportion of 70% found in
a recent global meta-analysis was applied [1].
Relative contribution
For each EU/EEA country, the estimated number of in-
fected cases among migrants from endemic countries
was divided by the total number of infected persons
(based on the general population CHC prevalence esti-
mate and the total population) to estimate the relative
contribution of migrants from endemic countries to the
overall number of people infected with CHC. Given un-
certainty in both the size of the migrant population and
CHC prevalence estimates in countries of birth, a range
in the relative contribution (a lower limit and a higher
limit) was also calculated using the Delta method [21].
Part 2: Anti-HCV prevalence in migrant populations in
Europe
The online databases Medline, Embase, the Cochrane li-
brary, Web of Science, Scopus, PubMed publisher and
Google Scholar were searched in November 2014 for
studies in English that estimate the prevalence of hepa-
titis C in migrants in any of the 31 EU/EEA countries.
The search used a combination of disease-related (hepa-
titis C), outcome-related (prevalence), population-related
(migrants) and geographical area (EU/EEA countries)
terms and was limited to studies published between
2000 and 2014. We expected a limited retrieval from this
search and therefore included only selection bias (how
representative the study population was of the general
population) as a key parameter in the risk of bias assess-
ment. This operationalised through the exclusion of
studies sampled from higher risk migrant groups such as
refugees/asylum seeker and higher risk (general) popula-
tions such as STI clinic attendees, outpatient clinics,
international health centres etc. The full search strategy,
inclusion/exclusion criteria and PRISMA flowchart are
available in the online supplement.
Data from the included studies were entered into
Microsoft Excel. Pooled estimates for countries of birth
were produced by combining the numbers tested and
the number of cases. A 95% CI was re-calculated using
the Fisher’s exact method. Prevalence estimates pooled
from multiple studies or extracted from large single
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studies (>25 subjects from a single country) were com-
pared with the in-country estimates to determine
whether in-country estimates reflect the prevalence
found among migrants. When the point prevalence from
a study in migrants (Part 2) fell within the CI/uncer-
tainty range of the in-country estimate (from Part 1),
this estimate was considered to be comparable; when it
fell below the lower CI/uncertainty range, it was consid-
ered to be lower than the in-country prevalence; and
when it was higher than the upper CI/uncertainty range,
it was considered to be higher.
Results
Estimated CHC prevalence and number of infected cases
in 31 EU/EEA countries (Table 1)
The anti-HCV prevalence in the general population in
the EU/EEA is estimated at 1.4% (range of 0.7–2.2%).
However, prevalence estimates range from 0.2% in the
Netherlands to 4.4% in Italy and 14 EU/EEA countries
are considered endemic by the definition adopted in our
study (≥1% anti-HCV prevalence). Table 1 lists the esti-
mated number and range of CHC cases among adults in
EU/EEA countries. An estimated 4.2 million (range 2.0–
6.6 million) adults in the EU/EEA have CHC infection.
Italy has the highest absolute number, with an estimated
1.6 million CHC cases. Other EU/EEA countries with a
high absolute number of CHC cases among adults are
Romania, with 380,000, and Spain, with 470,000.
The distribution of migrants in the EU/EEA based on HCV
endemicity in country of birth
The top 50 migrant populations in each EU/EEA coun-
try included in the analysis make up at least 95% of the
total migrant population in 19 countries and at least
90% in all but three EU/EEA countries (Denmark,
Sweden and the United Kingdom, where the proportion
is at least 85%). These migrant populations account for
approximately 10.7% of the total adult population in the
EU/EEA although the proportion in each country varies,
ranging from 0.7% in Romania, 1.1% in Bulgaria and
1.7% in Poland to 42.0% in Luxembourg and 65.2% in
Liechtenstein (Fig. 2).
Nearly 80% of the total migrant population were born
in HCV endemic countries. Other than in Slovakia,
where 23% of the total migrant population are from en-
demic countries, over half of all migrants in the other 30
EU/EEA countries were born in countries where the
anti-HCV prevalence is ≥1%. In Croatia, Estonia, Latvia,
Lithuania, Romania and Slovenia, more than 90% of all
migrants are from endemic countries (Fig. 2). The num-
ber and proportion of all migrants that from endemic
countries, at country level and in the EU/EEA as a whole
are shown in Table 2.
Country-specific anti-HCV prevalence estimates
The most comprehensive review with country-specific
estimates of anti-HCV prevalence identified by the
search was published in 2014 by Gower et al. [1]. This
review includes studies published after the year 2000
and provides estimates for 87 countries and for each of
the 21 Global Burden of Disease regions. The country-
level estimates from Gower do not have 95% CIs but a
lower and upper uncertainty range; the lower range is
based on studies among populations considered repre-
sentative of ‘healthy adults’ (such as blood donors), but
the methodology applied to derive the upper limit is un-
clear. For nine countries, Gower’s regional or in-country
estimate was replaced with estimates from other system-
atic reviews deemed more robust according to the cri-
teria described in the methods [2, 22–26]. The 224
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country-level prevalence estimates and the source, to-
gether with an overview of decision rationale where an
estimate other than Gower was available, are listed in
the online supplement.
Estimated prevalence and number of CHC infections
among migrants
Across the EU/EEA, the overall anti-HCV prevalence
among migrants from endemic countries is estimated at
2.3%, which corresponds to a CHC prevalence of 1.6%
and an estimated 580,000 CHC infections (Table 2). The
estimated prevalence of CHC infection among migrants
from endemic countries ranges from 0.9% in Croatia to
2.4% in Estonia. Table 2 lists the ten migrant populations
with the highest estimated number of CHC cases and
the host EU/EEA countries with the largest populations
of migrants born in these countries. Based on cumula-
tive analysis of the CHC burden among the different mi-
grant populations from endemic countries to or within
the EU, migrants from Romania, Russia, Italy and Poland
contribute most, in descending order, to the overall
number of CHC cases. An estimated 50,000–60,000
CHC cases are found among migrants from Romania
and from Russia.
Some countries of birth of migrants are common
across EU/EEA countries. Adult migrants from Russia, a
high CHC prevalence country (2.9%), are represented
among the top ten migrant populations in 25 of 31 EU/
EEA countries. Migrants from Romania and Italy are
among the top ten migrant groups in 20 EU/EEA
countries. Although small in number, migrants from
Egypt are among the top ten CHC-infected migrant pop-
ulations in 16 of 31 EU/EEA countries due the very high
anti-HCV prevalence (15.7%) in Egypt. In Estonia,
Lithuania and Latvia, the top ten migrant populations
with the highest number of infected cases are all from
countries of the former Soviet Union. This is also the
case in five to six of the top ten migrant populations
with the highest number of infected cases in Bulgaria,
the Czech Republic and Poland. People born either in
Yugoslavia before 1992 or in one of the countries that
emerged from the fall of Yugoslavia since 1992are repre-
sented in six of the top ten migrant populations with the
largest of number of CHC cases in Croatia and Slovenia
and three of the top ten in Austria. Migrants from the
Algeria, Morocco and Tunisia are represented among
the ten most CHC-affected migrant populations in
France. EU/EEA countries with three to five African
countries represented among the top ten CHC-affected
migrant groups include Belgium, France, Luxembourg,
Portugal and the UK. Prevalence, population size and
number and range of CHC infections among, for all 50
countries of birth of migrants in each EU/EEA country
can be found in the online supplement.
Relative contribution of migrants to the CHC burden in
EU/EEA countries
The relative proportion (and range) of infected migrants
from endemic countries within the overall CHC burden in
EU/EEA countries is shown in Table 1 and Fig. 3. The
relative contribution is low (<4%) in Bulgaria, Poland,
Romania and Slovakia and much higher (64%–92%) in
Cyprus, Liechtenstein, Luxembourg and the Netherlands.
Comparing migrant-derived anti-HCV prevalence with
country of birth estimates
The literature search identified thirteen anti-HCV preva-
lence estimates from studies in migrants in the EU/EEA
Table 2 The ten migrant groups (from endemic countries) accounting for the highest number of CHC cases
Migrant country of birth Total adult migrant
population
Anti-HCV
prevalence
Number (rounded) of
CHC cases
Host countries (first 6 with largest populations)a
Romania 2,646,392 3.2 59,000 Italy, Spain, Germany, Hungary, UK, Austria
Russia 1,713,636 4.1 49,000 Germany, Latvia, Estonia, Italy, Lithuania, Spain
Italy 1,114,683 4.4 34,000 France, Germany, UK, Belgium, Spain, The
Netherlands
Poland 4,103,409 1.1 32,000 Germany, UK, Italy, France, Ireland, The
Netherlands
Morocco 2,418,072 1.6 27,000 France, Spain, Italy, Belgium, The Netherlands,
Germany
Pakistan 756,170 5.0 27,000 UK, Italy, Spain, Germany, Greece, France
Ukraine 993,459 3.6 25,000 Poland, Germany, Italy, Czech Republic, Spain,
Latvia
Egypt 194,852 15.7 21,000 Italy, UK, France, The Netherlands, Austria, Greece
Kazakhstan 807,781 3.3 19,000 Germany, Latvia, Czech Republic, Poland,
Lithuania, Estonia
Nigeria 313,212 8.4 18,000 UK, Italy, Spain, Ireland, Austria, The Netherlands
aif migrant population is at least 1000
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for comparison with the in-country estimates derived in
Part 1. Two of the thirteen estimates, from studies
among migrants from the former Dutch Antilles and
Suriname, were higher than the comparator regional
prevalence [1]. One estimate, from a study among
migrants from the former Soviet Union, could not be
compared with in-country anti-HCV prevalence since
this nation state is now dissolved. Of the remaining ten
estimates, seven were comparable with the in-country
estimate and three, among migrants from Egypt,
Pakistan and Turkey, were lower than the in-country
prevalence (Egypt: 2.4% in migrants vs. 15.7% in-
country; Pakistan: 2.8% in migrants vs. 5.5% in-country;
and Turkey: 0.2% in migrants vs. 1.0% in-country),
although for Turkey the two confidence intervals
overlap. See Table 3 for details.
Discussion
This is the first study we know of that attempts to sys-
tematically estimate the overall number of CHC cases
among migrants, as well as the relative contribution of
cases among migrants to the overall burden of CHC in
EU/EEA countries. Migrants from endemic countries
account for one in 12 EU/EEA adult citizens and for one
in seven of all CHC cases in the EU/EEA. As the contri-
bution of migrants to the overall burden of CHC varies
between EU/EEA countries, effective approaches to sec-
ondary prevention will, therefore, also differ. Screening
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Fig. 3 Estimated relative contribution (upper/lower range) of migrants to the total number of CHC cases
Table 3 Comparing migrant study-derived prevalence to country of birth-derived prevalence
Country of birth Migrants In-country Comparison
N. tested Prevalence (95% CI) Reference Prevalence (95% CI) Reference
Afghanistan 293 1.0 (0.2–3.0) [32] 1.1 (0.6–1.9) [1] Comparable
Bangladesh 934 0.4 (0.1–1.1) [52, 53] 1.3 (0.2–2.2) [1] Comparable
Dutch Antilles 38 2.6 (0.1–13.8) [15, 45] 0.8b (0.2–1.3) [1] Higher
Egypt 465 2.4 (1.2–4.2) [54] 15.7 (13.9–17.5) [25] Lower
Former USSR 65 3.1 (0.4–10.7) [32] 3.3a (1.6–4.5) [1] Comparable
India 1334 0.4 (0.2–1.0) [52, 53] 0.8 (0.4–1.0) [1] Comparable
Iran 153 0.7 (0–3.6) [32] 0.5 (0.2 – 1a) [1] Comparable
Iraq 290 0.3 (0–1.9) [32] 3.2 (0.3–3.2a) [1] Comparable
Morocco 331 0.9 (0.2–2.6) [15, 45] 1.6 (0.6–1.9a) [1] Comparable
Pakistan 3562 2.8 (2.3–3.4) [30, 52, 53] 5.5 (4.4–5.5) [26] Lower
Suriname 225 2.4 (0.5–7.0) [15, 45] 0.8b (0.2–1.3) [1] Higher
Turkey 965 0.2 (0–0.8) [15, 45, 46] 1.0 (0.7–1.1) [22] Lower
Vietnam 126 1.6 (0.2–5.6) [32] 1.0 (0.8–1.8) [1] Comparable
aRegional estimate from GBD Eastern European region
bCaribbean GBD Regional estimate
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programmes targeting migrant populations will be most
effective in EU/EEA countries such as Austria, France,
Germany, the Netherlands and the UK where migrants
account for a large proportion of the disease burden
(32–92%, see Fig. 3) and a small proportion of the total
population (7–15%, see Fig. 2).
In contrast, in countries where HCV prevalence is
high in the general population and the contribution of
migrants is low, it may be more cost-effective to imple-
ment population-based screening [27, 28]. Examples of
such countries include Bulgaria, Poland, Romania and
Slovakia where less than 4% of the CHC burden is at-
tributable to migrants from endemic countries. The
differences in general population prevalence between
EU/EEA countries, together with the contribution of mi-
grants moving within the EU/EEA from high to low
prevalence countries, suggests that there may also be
value in allocating EU health funding to scale up and
systematise screening and treatment efforts in EU/EEA
countries with a high general population prevalence, to
strengthen efforts to reduce cross-border health threats
and to improve overall population health in the EU. A
recent modelling study estimated that only around a
third of all CHC cases across Europe have been diag-
nosed and that there are wide differences in both the
proportion diagnosed and the proportion on treatment
comparing EU/EEA countries [6]. There is however no
data on the estimated proportion of migrants from en-
demic countries that are diagnosed. The data reported,
as well as the strategies and interventions suggested, in
this study can contribute to increasing the proportion of
cases of CHC diagnosed and on treatment.
Previous studies of hepatitis B/C screening imple-
mented among migrant populations describe different
models. These include: outreach offering awareness
raising and/or on-site screening by public health teams
in social, civic or cultural locations familiar to the target
community [29–31]; invitation-based screening where
municipal, population or patient registries are used to
send postal invitations to attend screening to people
born in higher prevalence countries [32, 33]; opportunis-
tic offering of screening to patients with country of
birth-related risk factors who attend health care services
for other health issues [34, 35]; and adding viral hepatitis
screening to an existing screening programme, such as
for tuberculosis, that targets people from high preva-
lence countries [36]. Each of these models differs in
terms of logistical and resource requirements, uptake
and case yield, but few studies have compared the char-
acteristics and effectiveness of different models [37]. The
characteristics of screening programmes that have dem-
onstrated success in uptake and yield include: involve-
ment of the community in planning and raising
awareness; provision of screening in suitable and
accessible locations for the target community; provision
of language support, for example, translated materials
and interpreters; planning and provision for people with-
out health insurance coverage; cultural sensitivity about
and efforts to reduce or eliminate stigma; and availability
of follow-up and care in the community. Retention
within a follow-up care and treatment pathway is crucial
to ensure that the public health benefits of screening are
realised [38]. A summary of migrant-specific screening
programmes, an appraisal of factors contributing to suc-
cess, and a range of other scientific and practical re-
sources are available as part of the HEPscreen Toolkit,
produced by the EU-funded HEPscreen project, which
focused on screening for chronic viral hepatitis among
migrants [39].
In four countries, (Cyprus, Lichtenstein, Luxembourg
and the Netherlands) the upper range of the estimated
relative contribution of migrants as a proportion of the
total number of estimated cases was found to be over
100%. This reflects unmeasured correlation between the
input parameters (prevalence in countries of birth and
the size of the migrant population) for the Delta method
as well as the strong skew in the distribution of cases in
the general population in these countries. It is also pos-
sible that the prevalence in the general population in
these EU/EEA countries is under-estimated, due to
unrepresentative sampling or low participation of risk
populations who are harder to reach, such as PWID and
ethnic minorities as well as migrants. Under-
representation of migrants and ethnic minorities is a
widely recognised phenomenon in clinical trial and
health survey research, [40, 41] although literature spe-
cifically focused on sero-prevalence sampling and uptake
is very limited [23]. In addition, it is possible that
estimates based on prevalence in countries of birth re-
sults in over-estimation of the prevalence among mi-
grants. For example, it is probable that no longer living
in a high prevalence country would reduce the risk of
transmission of HCV, especially since much of the trans-
mission in higher prevalence countries is nosocomial
[42] and most EU/EEA countries have successfully
controlled nosocomial transmission through health care
infection control procedures. Over-estimation may also
be due to the characteristics of migrants to the EU/EEA,
who may be younger and healthier, and so less likely to
have experienced hospitalisation or serious medical
intervention and more likely to have benefited from im-
proved primary prevention in the last two decades. Mi-
grants to the EU may also be from higher socio-
economic groups in their countries of birth and able to
afford better, safer health care [43]. We sought to test
out this theory of over-estimation and found that, for
just three of the ten countries of birth for which we re-
trieved estimates for, [15, 29, 30, 44–47] the prevalence
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in migrants was lower than the reported in-country
prevalence.
Despite the systematic nature of data retrieval, there
are some data limitations. Detailed demographic data
was available from Eurostat for only 21 EU/EEA coun-
tries. There is also heterogeneity in the parameters and
methods used by the different demographic databases
and in the way that demographic data on migration is
collected and reported by EU/EEA countries. From other
literature, we know that countries such as Germany,
France and the Netherlands require municipal registra-
tion upon arrival in a new area and collect country of
birth data as part of registration. Other countries, like
the UK, rely on population census data to systematically
collect population size and origin [48]. However, there is
very limited information in the literature on the methods
used by each database or on the heterogeneity of demo-
graphic data collection methods across the EU/EEA.
Despite these differences, the demographic data used in
this study are derived from databases that in turn derive
data from national statistical institutes. We believe it to
be the best and most reputable available. These analyses
do not include undocumented migrants, partly because
the size and origin of this population is very dynamic,
but mostly because of the imprecision and unreliability
of the data [49]. The use of systematic reviews and
meta-analyses for the country of birth prevalence input
has reduced the reliance on less reliable single study es-
timates, and whilst we critically appraised the quality of
the systematic reviews and meta-analyses, which all ap-
plied quality criteria to select studies, we did not directly
assess the quality of the estimates included in these
reviews. A further note of caution relates to the studies
retrieved on prevalence in migrants, as just ten countries
of birth were represented in the estimates and few stud-
ies had the specific aim of estimating the prevalence in
migrants. The use of convenience sampling in many of
these studies increases the chance of selection bias and,
specifically, that people already diagnosed may not
present for screening.
Conclusions
Advances in antiviral treatment open up the possibility
of eliminating hepatitis C infection in Europe, but
achieving this will require countries to scale up and
better target screening, linkage to care and treatment.
This study provides strategic, timely and detailed epi-
demiological intelligence for EU/EEA countries on the
hepatitis C burden among migrant populations, a key
population group affected by this infection in Europe. It
also provides prevalence estimates for 224 countries and
territories, which should serve as a useful resource for
other countries and regions wishing to understand the
relative contribution of migrants to the burden of
hepatitis C. This intelligence, together with the learning
from previous migrant-specific screening projects in the
EU/EEA [39], can help to inform the design of screening
programmes to reach migrant populations most affected
by chronic hepatitis C infection. A targeted approach in
higher risk populations makes more effective use of
health care resources and contributes to reducing health
inequalities. The World Health Organisation’s Global
Strategy for Viral Hepatitis [50] and the European Ac-
tion Plan [51] both share the ambitious goal of elimin-
ation of viral hepatitis by 2030. If this goal is to be
realised, it will be essential to dramatically increase the
proportion of people who are diagnosed, aware of their
infection and on treatment. Future research can contrib-
ute by focussing on improving the evidence base on ef-
fective strategies to reach and retain migrant and other
risk populations in screening and treatment and on cost-
effectiveness across the treatment cascade.
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